This Article Full Text Full Text (PDF) Correction (v25,p472) All Versions of this Article: 25/1/18    most recent 01.ATV.0000149142.42590.a2v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nilsson, J. Articles by Shah, P. K. Search for Related Content PubMed PubMed Citation Articles by Nilsson, J. Articles by Shah, P. K. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Immunization Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:18.)
© 2005 American Heart Association, Inc.

Brief Reviews

Immunomodulation of Atherosclerosis

Implications for Vaccine Development—ATVB In Focus

Jan Nilsson; Göran K. Hansson; Prediman K. Shah

From the Department of Medicine (J.N.), Malmö University Hospital, Lund University, and the Department of Medicine and Center for Molecular Medicine (G.K.H.), Karolinska Institute, Sweden; and the Atherosclerosis Research Center and the Division of Cardiology (P.K.S.), Cedars-Sinai Medical Center, David Geffen School of Medicine at University of California, Los Angeles.

Correspondence to Jan Nilsson, University Hospital MAS, Entrance 33, First floor, S-205 02 Malmö, Sweden. E-mail Jan.Nilsson{at}medforsk.mas.lu.se

Series Editor: Göran K. Hansson

A number of studies have shown activation of the immune system throughout various stages of atherosclerosis. Recent observations have suggested that activation of immune responses may promote atherosclerosis on one hand by inducing and perpetuating arterial inflammation, whereas on the other hand, selective activation of certain immune functions may inhibit atherosclerosis and arterial inflammation. These observations suggest the possibility that selective suppression of proatherogenic immune responses or selective activation of antiatherogenic immune responses may provide new approaches for atherosclerosis prevention and treatment. Several antigens activating immune responses affecting development of atherosclerosis have been identified. These immune responses may be modulated by presenting the antigens together with different types of adjuvants as well as through the route of administration. In this review, we summarize recent experimental studies using immunomodulatory approaches for treatment of atherosclerosis.

The immune system is actively involved in development of atherosclerosis, mounting inflammatory responses promoting disease as well as specific protective responses. This review summarizes recent studies suggesting that influencing these responses by vaccines and means of immunomodulation may represent a novel therapy for prevention and treatment of atherosclerosis.

Key Words: atherosclerosis • vaccine • immunity • lipoproteins • heat shock proteins

Related Article:

ATVB In Focus: Immunity and Atherosclerosis

Göran K. Hansson
Arterioscler. Thromb. Vasc. Biol. 2005 25: 17. [Full Text] [PDF]

This article has been cited by other articles:

				L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello Role of Inflammation in Atherosclerosis J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815. [Abstract] [Full Text] [PDF]

				A. Strom, M. Wigren, A. Hultgardh-Nilsson, A. Saxena, M. F. Gomez, S. Cardell, G. N. Fredrikson, and J. Nilsson Involvement of the CD1d Natural Killer T Cell Pathway in Neointima Formation After Vascular Injury Circ. Res., October 12, 2007; 101(8): e83 - e89. [Abstract] [Full Text] [PDF]

				H. Ait-Oufella, B. Horvat, Y. Kerdiles, O. Herbin, P. Gourdy, J. Khallou-Laschet, R. Merval;, B. Esposito;, A. Tedgui, and Z. Mallat Measles Virus Nucleoprotein Induces a Regulatory Immune Response and Reduces Atherosclerosis in Mice Circulation, October 9, 2007; 116(15): 1707 - 1713. [Abstract] [Full Text] [PDF]

				E. Falk Pathogenesis of atherosclerosis. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C7 - C12. [Abstract] [Full Text] [PDF]

				A. Chamorro and J. Hallenbeck The Harms and Benefits of Inflammatory and Immune Responses in Vascular Disease Stroke, February 1, 2006; 37(2): 291 - 293. [Full Text] [PDF]

				M. Shinohara, S. Kawashima, T. Yamashita, T. Takaya, R. Toh, T. Ishida, T. Ueyama, N. Inoue, K.-i. Hirata, and M. Yokoyama Xenogenic smooth muscle cell immunization reduces neointimal formation in balloon-injured rabbit carotid arteries Cardiovasc Res, November 1, 2005; 68(2): 249 - 258. [Abstract] [Full Text] [PDF]

				K. J. Williams and I. Tabas Lipoprotein Retention--and Clues for Atheroma Regression Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1536 - 1540. [Abstract] [Full Text] [PDF]

				T. M. Doherty, P. K. Shah, M. Arditi, L. L. Stoll, G. M. Denning, and N. L. Weintraub Lipopolysaccharide, Toll-Like Receptors, and the Immune Contribution to Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): e38 - e39. [Full Text] [PDF]

				G. K. Hansson Inflammation, Atherosclerosis, and Coronary Artery Disease N. Engl. J. Med., April 21, 2005; 352(16): 1685 - 1695. [Full Text] [PDF]